India’s fledgling biotechnology industry, fuelled by exports and vaccine sales, grew 36 percent in the last fiscal year to clock revenues of 47.4 billion rupees (1.07 billion dollars), an industry body said. The Association of Biotechnology-Led Enterprises said exports of biotech products, driven by vaccines and statins and services such as contract research and clinical trials, accounted for 42 percent of total revenues at 20 billion rupees (444 million dollars).The biopharmaceutical industry alone grew almost 30 percent to 29.7 billion rupees in the year ended March 31, with vaccines contributing 47 percent of the total biopharma business.The association said six Indian biotechnology firms had crossed the one-billion-rupee (22 million dollar) revenue mark during the fiscal year against the previous year.
